MSB 12.1% 55.5¢ mesoblast limited

I think people should remind themselves of what the unblinded...

  1. 397 Posts.
    lightbulb Created with Sketch. 10873
    I think people should remind themselves of what the unblinded DMC has just opined in its last statement regarding their final interim meeting. They reviewed the primary endpoint and some of the most important secondary endpoints AS well as the safety data... and recommended the trial continues without alteration. It is my belief that the stopping rules agreed with the sponsor , require the DMC to stop the trial if Revascor fails to achieve certain meaningful thresholds in efficacy. As all the events required to reach the primary endpoint (531) had occurred when they carried out their interim analysis, I have to conclude this implies a very favourable result. It should be noted that neither Entresto or any of the SGLT2 based therapies have made any meaningful changes in treatment of Class 3 or 4 CHF. I think we have a very real probability of success. Even when you take into account the results of all the treatment dosages in the phase 2 trials there was still a substantial improvement versus control. I bought more shares today. Happy New Year to all ! OP
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
55.5¢
Change
0.060(12.1%)
Mkt cap ! $633.0M
Open High Low Value Volume
50.0¢ 59.0¢ 48.5¢ $16.88M 30.80M

Buyers (Bids)

No. Vol. Price($)
7 99223 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
56.0¢ 44000 4
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
55.5¢
  Change
0.060 ( 15.7 %)
Open High Low Volume
50.5¢ 59.0¢ 48.5¢ 11524458
Last updated 16.02pm 28/03/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.